Annemiek Visser1, Eline M W van de Ven2, Larissa I A Ruczynski2, Reinoud J B Blaisse3, Henk K van Halteren4, Katja Aben5,6, Hanneke W M van Laarhoven2,7. 1. a Department of Medical Psychology , Radboud university medical center , Nijmegen , The Netherlands. 2. b Department of Medical Oncology , Radboud university medical center , Nijmegen , The Netherlands. 3. c Department of Medical Oncology , Rijnstate, Arnhem , The Netherlands. 4. d Department of Medical Oncology , Gelderse Vallei, Ede , The Netherlands. 5. e Comprehensive Cancer Centre The Netherlands , Utrecht , The Netherlands. 6. f Department for Health Evidence , Radboud university medical center , Nijmegen , The Netherlands. 7. g Department of Medical Oncology , Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.
Abstract
BACKGROUND: Cardiotoxicity is an important adverse effect of adjuvant breast cancer treatment with trastuzumab and three monthly left ventricular ejection fraction (LVEF) monitoring is considered mandatory. The purpose of this study was to gain insight into LVEF monitoring during adjuvant trastuzumab treatment in clinical practice. MATERIAL AND METHODS: In a multicenter retrospective study encompassing 328 patients, of which 171 patients were actually treated with trastuzumab, we analyzed the frequency and mode of LVEF monitoring and compared it with LVEF monitoring guidelines. RESULTS: The results indicated poor guideline adherence. In 9% of patients trastuzumab was started in spite of a low LVEF (< 55%). In 24% of patients no valid baseline LVEF value was available. LVEF measurements during treatment at three, six and 12 months were only performed in, respectively, 53%, 40% and 30% of patients. CONCLUSION: A significant proportion of patients are treated with trastuzumab, while LVEF monitoring is not adequately performed. More attention should be paid to the implementation of (cardiac assessment) guidelines in clinical practice.
BACKGROUND:Cardiotoxicity is an important adverse effect of adjuvant breast cancer treatment with trastuzumab and three monthly left ventricular ejection fraction (LVEF) monitoring is considered mandatory. The purpose of this study was to gain insight into LVEF monitoring during adjuvant trastuzumab treatment in clinical practice. MATERIAL AND METHODS: In a multicenter retrospective study encompassing 328 patients, of which 171 patients were actually treated with trastuzumab, we analyzed the frequency and mode of LVEF monitoring and compared it with LVEF monitoring guidelines. RESULTS: The results indicated poor guideline adherence. In 9% of patientstrastuzumab was started in spite of a low LVEF (< 55%). In 24% of patients no valid baseline LVEF value was available. LVEF measurements during treatment at three, six and 12 months were only performed in, respectively, 53%, 40% and 30% of patients. CONCLUSION: A significant proportion of patients are treated with trastuzumab, while LVEF monitoring is not adequately performed. More attention should be paid to the implementation of (cardiac assessment) guidelines in clinical practice.
Authors: Daniel A Cehic; Aaron L Sverdlov; Bogda Koczwara; Jon Emery; Doan T M Ngo; Elysia Thornton-Benko Journal: Curr Treat Options Oncol Date: 2021-10-21
Authors: Monica Tang; Andrea L Schaffer; Belinda E Kiely; Benjamin Daniels; Chee K Lee; Robert J Simes; Sallie-Anne Pearson Journal: Breast Cancer Res Treat Date: 2021-02-22 Impact factor: 4.872
Authors: Nathalie I Bouwer; Agnes Jager; Crista Liesting; Marcel J M Kofflard; Jasper J Brugts; Jos J E M Kitzen; Eric Boersma; Mark-David Levin Journal: Breast Date: 2020-04-16 Impact factor: 4.380
Authors: Ena Niño de Guzmán; Yang Song; Pablo Alonso-Coello; Carlos Canelo-Aybar; Luciana Neamtiu; Elena Parmelli; Javier Pérez-Bracchiglione; Montserrat Rabassa; David Rigau; Zuleika Saz Parkinson; Iván Solà; Adrián Vásquez-Mejía; Ignacio Ricci-Cabello Journal: Breast Cancer Res Treat Date: 2020-05-06 Impact factor: 4.872
Authors: Sams Jaker; Amjad Burgan; Vineet Prakash; Alexander Birkinshaw; Kishan Moosai; Adam Jacques; David Fluck; Mark MacGregor; Otar Lazariashvili; Pankaj Sharma; Christopher H Fry; Thang S Han Journal: JRSM Cardiovasc Dis Date: 2020-03-24